ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ARDX Ardelyx Inc

6.475
0.085 (1.33%)
Last Updated: 11:40:05
Delayed by 15 minutes

Period:

Draw Mode:

Volume 2,256,501
Bid Price 6.47
Ask Price 6.48
News -
Day High 6.66

Low
3.16

52 Week Range

High
10.13

Day Low 6.42
Company Name Stock Ticker Symbol Market Type
Ardelyx Inc ARDX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.085 1.33% 6.475 11:40:05
Open Price Low Price High Price Close Price Prev Close
6.45 6.42 6.66 6.39
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
8,237 2,256,501 $ 6.52 $ 14,706,934 - 3.16 - 10.13
Last Trade Time Type Quantity Stock Price Currency
11:40:20 99 $ 6.47 USD

Ardelyx Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.53B 232.69M - 124.46M -66.07M -0.28 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Ardelyx News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ARDX Message Board. Create One! See More Posts on ARDX Message Board See More Message Board Posts

Historical ARDX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week6.836.846.276.484,348,790-0.355-5.20%
1 Month7.537.876.277.075,217,488-1.06-14.01%
3 Months8.9210.136.278.265,517,197-2.45-27.41%
6 Months3.4410.133.437.095,865,5633.0488.23%
1 Year5.0010.133.165.515,861,9631.4829.50%
3 Years8.3510.130.49023.016,814,672-1.88-22.46%
5 Years3.5310.43430.49023.284,374,2792.9583.43%

Ardelyx Description

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

Your Recent History

Delayed Upgrade Clock